The findings show improvements across multiple patient-reported outcomes in patients switching to intravenous (IV) eptinezumab, despite high disease burden.

These real-world data strengthen our confidence in eptinezumab’s ability to deliver meaningful improvements in migraine burden, not only in clinical trials, but in everyday clinical practice.

“These real-world data strengthen our confidence in eptinezumab’s ability to deliver meaningful improvements in migraine burden, not only in clinical trials, but in everyday clinical practice,” says Johan Luthman, EVP and Head of Research & Development at Lundbeck. “INFUSE demonstrates that patients receiving eptinezumab report consistent reductions in migraine frequency and improvements in everyday functioning, even in participants who previously experienced limited benefit from preventive aCGRPs.”

The INFUSE study

The INFUSE study is an ongoing observational, prospective study in which people with migraine were recruited through two Vyepti Infusion Network partners in the US. This study includes adults in whom ≥1 preventive aCGRP had failed due to a lack of effectiveness or side effects, with no specific time frame between treatments required, according to protocol. This analysis reports the findings in participants who successfully completed a full six months of treatment with eptinezumab (n=111). Safety data was not collected in the study, however reported via standard safety reporting channels.

After two infusions of eptinezumab, 75.7% of participants reported an improvement (any level) in migraine status, as measured by the Patient Global Impression of Change Scale (PGIC) with 44.1% reporting “much improved,” or “very much improved” . 44.1% of participants reported a ≥50% reduction in monthly headache days (MHDs), with a mean reduction of 6.8 MHDs from a baseline of 20.0 MHDs. Additionally, 26.1% of participants achieved >75% reduction in MHD at Month 6.    

Patients also reported an average increase of 6.3 additional “good days” per month compared with baseline. Together these findings reflect notable reductions in migraine frequency and improvements in day-to-day functioning, suggesting a potential clinical benefit in considering eptinezumab earlier in the treatment pathway.

Eptinezumab 

Eptinezumab has been shown to be well tolerated across multiple clinical trials. The safety of eptinezumab has been evaluated in more than 2,000 adult patients with migraine who received at least one dose of eptinezumab. During the registrational trials, PROMISE-1 and PROMISE-2, the most common adverse reactions were nasopharyngitis and hypersensitivity.